Loading...
Docoh

AC Immune (ACIU)

News

From Benzinga Pro
Stocks That Hit 52-Week Lows On Wednesday
11 May 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
On Wednesday, 807 companies reached new 52-week lows.
AC Immune Reports Its Anti-Abeta Vaccine Results From Phase 1b Study In Down Syndrome Were Published In 'JAMA Neurology'
9 May 22
Biotech, News, FDA, General
First study of an anti-Abeta vaccine in people living with Down syndrome (DS) Immune response and Alzheimer’s disease (AD) biomarkers showed positive impact of ACI-24 first generation vaccine Optimized
Stocks That Hit 52-Week Lows On Friday
6 May 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
On Friday, 1043 companies hit new 52-week lows.
Stocks That Hit 52-Week Lows On Thursday
28 Apr 22
News, Options, Intraday Update, Markets
During Thursday, 849 stocks hit new 52-week lows.
Recap: AC Immune Q1 Earnings
28 Apr 22
Earnings, News
AC Immune (NASDAQ:ACIU) reported its Q1 earnings results on Thursday, April 28, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
AC Immune Says KOL Webinar On First Clinical Proof Of Concept For Alpha-Synuclein Diagnostic Shows Breakthrough Potential For Neurodegenerative Diseases
30 Mar 22
News, FDA, Events
AC Immune KOL Webinar on First Clinical Proof of Concept for Alpha-synuclein Diagnostic Shows Breakthrough Potential for Neurodegenerative diseases a-syn PET tracer, ACI-12589, clinically validated in MSA, potentially
AC Immune: Q4 Earnings Insights
22 Mar 22
Earnings
AC Immune (NASDAQ:ACIU) reported its Q4 earnings results on Tuesday, March 22, 2022 at 07:30 AM. Here's what investors need to know about the announcement. Earnings AC Immune reported an EPS of $-0.28.
AC Immune Reports FY21 Cash Balance Of CHF198.2M
22 Mar 22
Earnings, News
Analysis of Financial Statements for the year ended December 31, 2021 Cash Position: The Company had a total cash balance of CHF 198.2 million, composed of CHF 82.2 million in cash and cash equivalents and CHF
The Daily Biotech Pulse: Moderna Files For 2nd COVID Booster Shot Authorization, Lexicon Secures Debt Funding, Amneal Gets Sub-License to Manufacture Generic COVID Pill
18 Mar 22
Biotech, News, Penny Stocks, Small Cap, FDA, Top Stories, General
Here's a roundup of top developments in the biotech space over the last 24 hours.
AC Immune Reports First Live Images Of Alpha-Synuclein In Human Brain With New PET Tracer For Neurodegenerative Disease At AD/PDTM Conference
16 Mar 22
News, Events
ACI-12589 distinguished multiple system atrophy (MSA) from other a-synucleinopathies and healthy volunteers A-syn PET tracers may be developed to diagnose a-synuclein pathologies, including Parkinson's
The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings
13 Mar 22
Biotech, Earnings, News, Penny Stocks, Small Cap, FDA, Top Stories, General
Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments served as catalysts during the week.
Stocks That Hit 52-Week Lows On Monday
7 Mar 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
On Monday, 524 stocks hit new 52-week lows.
AC Immune-Janssen Partnered Alzheimer's Vaccine Shows Tau-Specific Antibodies In Early-Stage Trial
15 Feb 22
Biotech, News, Penny Stocks, Health Care, Small Cap, Movers, Trading Ideas, General
AC Immune SA (NASDAQ: ACIU) and partner Janssen, a unit of Johnson & Johnson (NYSE: JNJ), have found that an early-stage Alzheimer's vaccine spurs induction of antibodies that attack a type of tau, a
AC Immune ACI-35.030 Phase 1b/2a Trial Interim Data Confirm Consistent Safety And Potent Immunogenicity Of pTau Alzheimer's Vaccine In High-dose Cohort
15 Feb 22
Biotech, News, FDA, General
AC Immune SA (NASDAQ:ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced new interim 10-week data from the high-dose cohort of a

Press releases

From Benzinga Pro
AC Immune's Anti-Abeta Vaccine Results from Phase 1b Study in Down Syndrome Published in JAMA Neurology
9 May 22
Health Care, Press Releases
First study of an anti-Abeta vaccine in people living with Down syndrome (DS) Immune response and Alzheimer's disease (AD) biomarkers showed positive impact of ACI-24 first generation vaccine Optimized formulation of
AC Immune Reports First Quarter 2022 Financial Results and Provides Corporate Update
28 Apr 22
Earnings, Press Releases
Two clinical readouts delivered in Q1; five more expected by year-end Interim data from the Phase 1b/2a trial of ACI-35.030 confirm the favorable safety and potent immunogenicity of this first-in-class anti-pTau
AC Immune to Present at the B. Riley Annual Neuro & Ophthalmology Virtual Investor Conference
27 Apr 22
News, Press Releases
LAUSANNE, Switzerland, April 27, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that
AC Immune Reports Changes to Senior Management
8 Apr 22
News, Management, Press Releases
Howard Donovan appointed Chief HR Officer, joins executive committee Joerg Hornstein, CFO, will leave to pursue new role Chris Roberts promoted to Vice President, Finance and appointed Interim CFO Julian Snow promoted
AC Immune KOL Webinar on First Clinical Proof of Concept for Alpha-synuclein Diagnostic Shows Breakthrough Potential for Neurodegenerative diseases
30 Mar 22
Health Care, Press Releases
a-syn PET tracer, ACI-12589, clinically validated in MSA, potentially enables accelerated development of targeted therapeutics and additional a-syn diagnostics Another first for validated Morphomer® discovery
AC Immune Reports Full Year 2021 Financial Results and Provides Corporate Update
22 Mar 22
Earnings, Press Releases
Seven clinical data readouts expected in 2022Three vaccines, targeting Tau, Abeta and alpha-synuclein, advancing in 2022Semorinemab Phase 2 Lauriet trial: additional fluid biomarker data expected in H2 2022Initiation of
AC Immune to Host Key Opinion Leader Webinar on Alpha-Synuclein as a Target in Neurodegenerative Diseases
21 Mar 22
Health Care, Press Releases
LAUSANNE, Switzerland, March 21, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ:ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, will host a key
AC Immune Reports First Live Images of Alpha-Synuclein in Human Brain with New PET Tracer for Neurodegenerative Disease at AD/PDTM Conference
16 Mar 22
Health Care, Press Releases
ACI-12589 distinguished multiple system atrophy (MSA) from other a-synucleinopathies and healthy volunteers A-syn PET tracers may be developed to diagnose a-synuclein pathologies, including Parkinson's disease, Lewy
AC Immune to Present at the AD/PD™ 2022 New Clinical and Preclinical Data for Alpha-Synuclein, Abeta and TDP-43 Programs
28 Feb 22
News, Health Care, Press Releases
Five presentations at the International Conference on Alzheimer's & Parkinson's Diseases (AD/PDTM) AC Immune's Chief Medical Officer to participate in expert forum on translational drug discovery for
AC Immune ACI-35.030 Phase 1b/2a Trial Interim Data Confirm Consistent Safety and Potent Immunogenicity of pTau Alzheimer's Vaccine in High-dose Cohort
15 Feb 22
Health Care, Analyst Ratings, Press Releases
Observed strong induction of antibodies specific for pathological forms of Tau with ACI-35.030 treatment ACI-35.030 continues to be well tolerated with no clinically relevant safety concerns observed in low-, mid- or